Gene Detail

Filtering

Case insensitive filtering will display rows where any text in any cell matches the filter term
Simple literal full or partial string matches
Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance
FGFR3 - TACC3	fusion	gain of function	FGFR3-TACC3 results from the fusion of FGFR3 and TACC3, demonstrating constitutive kinase activity, transforming activity in culture and ability to drive tumor growth in xenografts (PMID: 25294908, PMID: 22837387).
R248C	missense	gain of function	FGFR3 R248C lies within the extracellular domain of the Fgfr3 protein (UniProt.org). R248C confers a gain of function to the Fgfr3 protein as demonstrated by constitutive ligand-independent cell proliferation (PMID: 19381019) and increased activation of the Mapk signaling pathway (PMID: 24626198).
D786N	missense	gain of function - predicted	FGFR3 D786N does not lie within any known functional domains of the Fgfr3 protein (UniProt.org). D786N has not been biochemically characterized, but is predicted to confer a gain of function on the Fgfr3 protein as demonstrated by increased transformation ability (PMID: 29533785).
A391E	missense	gain of function	FGFR3 A391E lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). A391E results in increased dimerization and ligand-independent activation of Fgfr3 in cell culture (PMID: 21536014, PMID: 23437153)
E360Q	missense	loss of function - predicted	FGFR3 E360Q does not lie within any known functional domains of the Fgfr3 protein (UniProt.org). E360Q has not been biochemically characterized, but is predicted to confer a loss of function on the Fgfr3 protein as demonstrated by decreased transformation ability as compared to wild-type Fgfr3 (PMID: 29533785).
K413N	missense	unknown	FGFR3 K413N lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). K413N has been identified in the scientific literature (PMID: 25056374), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
K650N	missense	gain of function - predicted	FGFR3 K650N lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650N results in constitutive activation of the Fgfr3 protein (PMID: 11055896) and therefore, is predicted to result in a gain of Fgfr3 protein function.
L794R	missense	unknown	FGFR3 L794R lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). L794R has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
K650T	missense	gain of function - predicted	FGFR3 K650T lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650T results in constitutive activation of the Fgfr3 protein (PMID: 11055896) and therefore, is predicted to result in a gain of Fgfr3 protein function.
V677I	missense	no effect	FGFR3 V677I lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V677I demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).
amp	unknown	no effect	FGFR3 amp indicates an increased number of copies of the FGFR3 gene. However, the mechanism causing the increase is unspecified.
mutant	unknown	unknown	FGFR3 mutant indicates an unspecified mutation in the FGFR3 gene.
S371C	missense	gain of function	FGFR3 S371C lies within the extracellular domain of the Fgfr3 protein (UniProt.org). S371C confers a gain of function to the Fgfr3 protein, resulting in dimerization, constitutive activation, and increased MAPK pathway signaling (PMID: 12009017).
P283S	missense	unknown	FGFR3 P283S lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). P283S has been identified in sequencing studies (PMID: 26003532, PMID: 27998968), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
V306I	missense	unknown	FGFR3 V306I lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). V306I has been identified in the scientific literature (PMID: 23443805), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
D764H	missense	unknown	FGFR3 D764H (corresponds to D762H in the canonical isoform) lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). D764H has not been fully biochemically characterized, and is conflicting as it results in increased proliferation in some cell culture conditions, but not others (PMID: 27053219) and therefore, its effect on Fgfr3 protein function is unknown.
F384L	missense	no effect	FGFR3 F384L lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). F384L does not result in activation of Fgfr3 and is not transforming in cell culture (PMID: 11157491, PMID: 29533785).
K319del	missense	no effect - predicted	FGFR3 K319del results in the deletion of an amino acid in the Fgfr3 protein at amino acid 319 (UniProt.org). K319del has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
V172I	missense	loss of function - predicted	FGFR3 V172I lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). V172I has not been biochemically characterized, but is predicted to confer a loss of function on the Fgfr3 protein as demonstrated by decreased transformation ability in cell culture as compared to wild-type Fgfr3 (PMID: 29533785).
T79S	missense	unknown	FGFR3 T79S lies within the Ig-like C2-type domain 1 of the Fgfr3 protein (UniProt.org). T79S has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
R805Q	missense	no effect - predicted	FGFR3 R805Q does not lie within any known functional domains of the Fgfr3 protein (UniProt.org). R805Q has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
D646Y	missense	no effect	FGFR3 D646Y lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). D646Y demonstrates autophosphorylation and substrate phosphorylation similar to the level of wild-type Fgfr3 in cell culture (PMID: 26992226).
L794fs	frameshift	unknown	FGFR3 L794fs results in a change in the amino acid sequence of the Fgfr3 protein beginning at aa 794 of 806, likely resulting in a premature truncation of the functional protein (UniProt.org). L794fs has been identified in sequencing studies (PMID: 25157968), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
N653H	missense	no effect	FGFR3 N653H lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). N653H demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).
E456K	missense	unknown	FGFR3 E456K lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). E456K has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2018).
Y375C	missense	gain of function	FGFR3 Y375C (corresponds to Y373C in the canonical isoform) lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). Y375C confers a gain of function to the Fgfr3 protein as demonstrated by ligand-independent constitutive phosphorylation in vitro and transformation of cells in culture (PMID: 19749790).
inact mut	unknown	loss of function	FGFR3 inact mut indicates that this variant results in a loss of function of the Fgfr3 protein. However, the specific amino acid change has not been identified.
G235D	missense	unknown	FGFR3 G235D lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). G235D has been identified in the scientific literature (PMID: 27271022), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
D788N	missense	unknown	FGFR3 D788N (corresponds to D785N in the canonical isoform) lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). D788N has not been fully biochemically characterized, and is conflicting as it results in increased proliferation in some cell culture conditions, but not others (PMID: 27053219) and therefore, its effect on Fgfr3 protein function is unknown.
E322K	missense	unknown	FGFR3 E322K lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). E322K has been identified in sequencing studies (PMID: 26003532, PMID: 11325814), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
V700A	missense	unknown	FGFR3 V700A lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V700A has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
S351C	missense	loss of function - predicted	FGFR3 S351C lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). S351C has not been biochemically characterized, but is predicted to confer a loss of function on the Fgfr3 protein as demonstrated by decreased transformation ability in cell culture as compared to wild-type Fgfr3 (PMID: 29533785).
R669Q	missense	gain of function - predicted	FGFR3 R669Q lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R669Q results in increased Fgfr3 autophosphorylation in cell culture (PMID: 26992226) and therefore, is predicted to result in a gain of Fgfr3 protein function.
Y647C	missense	gain of function - predicted	FGFR3 Y647C lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). Y647C results in increased Fgfr3 autophosphorylation in cell culture (PMID: 26992226) and therefore, is predicted to result in a gain of Fgfr3 protein function.
V50I	missense	gain of function - predicted	FGFR3 V50I lies within the Ig-like C2-type domain 1 of the Fgfr3 protein (UniProt.org). V50I has not been biochemically characterized, but is predicted to confer a gain of function on the Fgfr3 protein as demonstrated by increased transformation ability in cell culture (PMID: 29533785).
R640W	missense	unknown	FGFR3 R640W lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R640W has been identified in sequencing studies (PMID: 26517354), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
C582F	missense	no effect	FGFR3 C582F lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). C582F demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).
G197S	missense	unknown	FGFR3 G197S lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). G197S has been identified in sequencing studies (PMID: 17344920), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
Y373C	missense	gain of function	FGFR3 Y373C lies within the extracellular domain of the Fgfr3 protein (UniProt.org). Y373C confers a gain of function to the Fgfr3 protein resulting in constitutive activation, downstream signaling, and transformation of cultured cells (PMID: 11429702).
K508M	missense	loss of function	FGFR3 K508M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K508M confers a loss of function to the Fgfr3 protein as demonstrated by induction of growth arrest in cell culture and inactivation of Stat1 in vitro (PMID: 19088846) and loss of kinase activity in the context of Fgfr3-Tacc3 (PMID: 22837387).
G697C	missense	no effect	FGFR3 G697C lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). G697C demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3, and is not transforming in cell culture (PMID: 26992226).
I376C	missense	unknown	FGFR3 I376C lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). I376C has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
dec exp	none	no effect	FGFR3 dec exp indicates decreased expression of the Fgfr3 protein. However, the mechanism causing the decreased expression is unspecified.
R421Q	missense	unknown	FGFR3 R421Q lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). R421Q has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
D617G	missense	loss of function - predicted	FGFR3 D617G lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). D617G results in a loss of Fgfr3 activity in cell culture (PMID: 26992226) and therefore, is predicted to result in a loss of Fgfr3 protein function.
S249C	missense	gain of function	FGFR3 S249C lies within the linker region between IgD2 and IgD3 of the Fgfr3 protein (PMID: 19381019). S249C confers a gain of function to the Fgfr3 protein as demonstrated by stabilized homodimer formation and constitutive phosphorylation in vitro (PMID: 17384684) and constitutive ligand-independent cell proliferation in culture (PMID: 19381019, PMID: 29533785).
F386L	missense	unknown	FGFR3 F386L lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). F386L is a common Fgfr3 polymorphism (PMID: 19377444), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
K652E	missense	gain of function - predicted	FGFR3 K652E (corresponds to K649E in the canonical isoform) lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K652E was demonstrated to induce transformation of mouse fibroblasts, but had a lesser degree of signaling and phenotypic effect in immortalized normal human urothelial cells (PMID: 19749790) and therefore, is predicted to result in a gain of Fgfr3 protein function.
P795A	missense	unknown	FGFR3 P795A lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). P795A has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
V329A	missense	unknown	FGFR3 V329A lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). V329A has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
L645V	missense	unknown	FGFR3 L645V lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). L645V has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
P253_I254insHIA	insertion	unknown	FGFR3 P253_I254insHIA results in the insertion of three amino acids in the Ig-like C2-type domain 3 of the Fgfr3 protein between amino acids 253 and 254 (UniProt.org). P253_I254insHIA has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
D762H	missense	no effect - predicted	FGFR3 D762H does not lie within any known functional domains of the Fgfr3 protein (UniProt.org). D762H has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
H643D	missense	no effect	FGFR3 H643D lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). H643D demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).
G382R	missense	gain of function	FGFR3 G382R lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). G382R results in increased Fgfr3 protein dimerization and constitutive activation (PMID: 16841094), and has also been shown to inhibit receptor internalization (PMID: 17172848).
V555M	missense	gain of function	FGFR3 V555M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V555M results in increased Fgfr3 autophosphorylation and substrate phosphorylation in cell culture (PMID: 26992226).
N540S	missense	gain of function - predicted	FGFR3 N540S lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). N540S results in increased Fgfr3 autophosphorylation in cell culture (PMID: 26992226) and therefore, is predicted to result in a gain of Fgfr3 protein function.
V390M	missense	no effect - predicted	FGFR3 V390M does not lie within any known functional domains of the Fgfr3 protein (UniProt.org). V390M has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
S187Y	missense	no effect - predicted	FGFR3 S187Y lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). S187Y has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
I538F	missense	no effect	FGFR3 I538F lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). I538F demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).
R603Q	missense	unknown	FGFR3 R603Q lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R603Q has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
S400fs	frameshift	loss of function - predicted	FGFR3 S400fs results in a change in the amino acid sequence of the Fgfr3 protein beginning at aa 400 of 806, likely resulting in a premature truncation of the functional protein (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), S400fs is predicted to lead to a loss of Fgfr3 protein function.
D222N	missense	unknown	FGFR3 D222N lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). D222N has been identified in the scientific literature (PMID: 27271022), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
fusion	fusion	unknown	FGFR3 fusion indicates a fusion of the FGFR3 gene, but the fusion partner is unknown.
S679F	missense	unknown	FGFR3 S679F lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). S679F has been identified in sequencing studies (PMID: 27998968) but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
R124W	missense	gain of function - predicted	FGFR3 R124W lies within the Ig-like C2-type domain 1 of the Fgfr3 protein (UniProt.org). R124W has not been biochemically characterized, but is predicted to confer a gain of function on the Fgfr3 protein as demonstrated by increased transformation ability in cell culture (PMID: 29533785).
G637W	missense	loss of function - predicted	FGFR3 G637W lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). G637W results in a loss of Fgfr3 kinase activity in cell culture (PMID: 26992226) and therefore, is predicted to result in a loss of Fgfr3 protein function.
T394M	missense	no effect - predicted	FGFR3 T394M does not lie within any known functional domains of the Fgfr3 protein (UniProt.org). T394M has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
G65R	missense	unknown	FGFR3 G65R lies within the Ig-like C2-type domain 1 of the Fgfr3 protein (UniProt.org). G65R has not been characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
V630M	missense	no effect	FGFR3 V630M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V630M demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).
Q209H	missense	unknown	FGFR3 Q209H lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). Q209H has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
P572A	missense	no effect	FGFR3 P572A lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). P572A demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).
V555L	missense	unknown	FGFR3 V555L lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V555L has not been biochemically has been demonstrated to confer resistance to Fgfr inhibitors in cell culture (PMID: 28034880), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).	Y
G372C	missense	gain of function	FGFR3 G372C (equivalent to G370C in isoform1) lies within the extracellular domain of the Fgfr3 protein (UniProt.org). G372C confers a gain of function on Fgfr3, as indicated by ligand-independent phosphorylation and dimerization of Fgfr3, and activation of MAPK pathway in cell culture (PMID: 16841094, PMID: 12009017).
G380R	missense	gain of function	FGFR3 G380R lies within the transmembrane domain of the Fgfr3 protein (PMID: 20624921). G380R results in increased ligand-independent phosphorylation of Fgfr3 and enhanced ligand-dependent activation of downstream signaling, but is not transforming in cell culture (PMID: 20624921, PMID: 9136983, PMID: 10611230).
K650E	missense	gain of function - predicted	FGFR3 K650E lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650E results in constitutive activation of the Fgfr3 protein (PMID: 11055896) and therefore, is predicted to result in a gain of Fgfr3 protein function.
L608V	missense	unknown	FGFR3 L608V lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). L608V has been demonstrated to confer resistance to Fgfr inhibitors in cell culture (PMID: 28034880), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).	Y
Y241C	missense	unknown	FGFR3 Y241C lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). Y241C has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
R248H	missense	unknown	FGFR3 R248H lies within the extracellular domain of the Fgfr3 protein (UniProt.org). R248H has been identified in the scientific literature (PMID: 24452392), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
K650Q	missense	gain of function - predicted	FGFR3 K650Q lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650Q has not been characterized, however other K650 mutations result in constitutive activation of the Fgfr3 protein thus K650Q is predicted to result in a gain of function (PMID: 11055896).
P91L	missense	unknown	FGFR3 P91L lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). P91L has been identified in the scientific literature (PMID: 26907448), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
act mut	unknown	gain of function	FGFR3 act mut indicates that this variant results in a gain of function in the FGFR3 protein. However, the specific amino acid change has not been identified.
E216K	missense	unknown	FGFR3 E216K lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). E216K has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
K715M	missense	unknown	FGFR3 K715M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K715M has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
Q256R	missense	unknown	FGFR3 Q256R lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). Q256R has been identified in sequencing studies (PMID: 28199989) but has not been biochemically and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
A452S	missense	no effect - predicted	FGFR3 A452S does not lie within any known functional domains of Fgfr3 protein (UniProt.org). A452S has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
FGFR3 - BAIAP2L1	fusion	gain of function	FGFR3-BAIAP2L1 results from the fusion of FGFR3 and BAIAP2L1, demonstrating constitutive activation and transformation of cells in culture (PMID: 23175443).
A634T	missense	unknown	FGFR3 A634T lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). A634T has not been biochemically characterized and demonstrates decreased transformation ability in one of two different cell lines as compared to wild-type Fgfr3 (PMID: 29533785) and therefore, its effect on Fgfr3 protein function is unknown.
R112Q	missense	unknown	FGFR3 R112Q lies within the Ig-like C2-type domain 1 of the Fgfr3 protein (UniProt.org). R112Q has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
K650M	missense	gain of function	FGFR3 K650M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650M confers a gain of function to the Fgfr3 protein as demonstrated by ligand-dependent autophosphorylation, activation of Mapk signaling (PMID: 9857065), and activation of Stat1 in kinase assays (PMID: 19088846).
wild-type	none	no effect	Wild-type FGFR3 indicates that no mutation has been detected within the FGFR3 gene.
A391V	missense	no effect - predicted	FGFR3 A391V lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). A391V has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Fgfr3 in culture (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
rearrange	unknown	unknown	FGFR3 rearrangement indicates an unspecified rearrangement of the FGFR3 gene.
G370C	missense	gain of function	FGFR3 G370C lies within the juxtamembrane region of the Fgfr3 protein (PMID: 12009017). G370C confers a gain of function to the Fgfr3 protein, resulting in increased Fgfr3 phosphorylation compared to wild-type and constitutive activation of the mitogen activated protein kinase (MAPK) signaling pathway (PMID: 12009017).
C228R	missense	gain of function - predicted	FGFR3 C228R lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). C228R results in stabilization of Fgfr3 dimers in culture (PMID: 27596331) and therefore, is predicted to result in a gain of Fgfr3 protein function.
R669G	missense	gain of function	FGFR3 R669G lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R669G results in increased Fgfr3 autophosphorylation and substrate phosphorylation in cell culture (PMID: 26992226).
V788M	missense	gain of function - predicted	FGFR3 V788M does not lie within any known functional domains of the Fgfr3 protein (UniProt.org). V788M has not been biochemically characterized, but is predicted to confer a gain of function on the Fgfr3 protein as demonstrated by increased transformation ability in cell culture (PMID: 29533785).
G382D	missense	gain of function - predicted	FGFR3 G382D lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). G382D results in constitutive activation of Fgfr3 and downstream signaling, but is not transforming in cell culture (PMID: 11429702).
N540V	missense	unknown	FGFR3 N540V lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). N540V has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
H274Y	missense	no effect - predicted	FGFR3 H274Y lies within the Ig-like C2 type domain 3 of the Fgfr3 protein (UniProt.org). H274Y has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
I538V	missense	gain of function - predicted	FGFR3 I538V lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). I538V results in increased Fgfr3 autophosphorylation in cell culture (PMID: 26992226) and therefore, is predicted to result in a gain of Fgfr3 protein function.
FGFR3 - ELAVL3	fusion	unknown	FGFR3-ELAVL3 results from the fusion of FGFR3 and ELAVL3 (PMID: 25204415). FGFR3-ELAVL3 has been identified in glioma (PMID: 25204415, PMID: 26061751), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Jan 2018).
D785N	missense	no effect - predicted	FGFR3 D785N does not lie within any known functional domains of the Fgfr3 protein (UniProt.org). D785N has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
Y379C	missense	unknown	FGFR3 Y379C lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). Y379C has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
E627D	missense	no effect	FGFR3 E627D lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). E627D demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).
R399C	missense	no effect - predicted	FGFR3 R399C lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). R399C has not been biochemically characterized, but results in similar cell proliferation and viability levels to wild-type Fgfr3 in culture (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
over exp	none	no effect	FGFR3 over exp indicates an over expression of the Fgfr3 protein. However, the mechanism causing the over expression is unspecified.
S433C	missense	unknown	FGFR3 S433C lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). S433C has been identified in the scientific literature (PMID: 17344920), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
G384D	missense	unknown	FGFR3 G384D (corresponds to G382D in the canonical isoform) lies within a pentameric consensus region in the transmembrane domain of the Fgfr3 protein (PMID: 11429702). G384D has variable effects on activation of Fgfr3, and is not transforming in cell culture (PMID: 11429702), and therefore, its effect on Fgfr3 protein function is unknown.
L385M	missense	unknown	FGFR3 L385M lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). L385M has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
positive	unknown	unknown	FGFR3 positive indicates the presence of the ESR1 gene, mRNA, and/or protein.
H349Y	missense	unknown	FGFR3 H349Y lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). H349Y has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
R200C	missense	gain of function	FGFR3 R200C lies within the Ig-like C2-type 2 domain of the Fgfr3 protein (UniProt.org). R200C confers a gain of function to the Fgfr3 protein resulting in dimerization and constitutive activation (PMID: 16912704).
S131L	missense	unknown	FGFR3 S131L lies within the extracellular domain of the Fgfr3 protein (UniProt.org). S131L has not been biochemically characterized, but results in increased proliferation under some cell culture conditions (PMID: 27053219), and in another study, S131L had decreased cell proliferation and cell viability as compared to wild-type Fgfr3 (PMID: 29533785).
V642M	missense	no effect - predicted	FGFR3 V642M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V642M has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
S780C	missense	no effect - predicted	FGFR3 S780C does not lie within any known functional domains of the Fgfr3 protein (UniProt.org). S780C has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
E466K	missense	no effect	FGFR3 E466K lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). E466K demonstrates Fgfr3 autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).
A500T	missense	no effect	FGFR3 A500T lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). A500T demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).
G710D	missense	unknown	FGFR3 G710D lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). G710D has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
D641N	missense	gain of function	FGFR3 D641N lies within the TK-2 domain of the Fgfr3 protein (PMID: 19287463). D641N results in increased Fgfr3 autophosphorylation and substrate phosphorylation in cell culture (PMID: 26992226).
P402S	missense	no effect - predicted	FGFR3 P402S does not lie within any known functional domains of the Fgfr3 protein (UniProt.org). P420S has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Fgfr3 (PMID: 29533785) and therefore, is predicted to have no effect on Fgfr3 protein function.
A341T	missense	unknown	FGFR3 A341T lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). A341T has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
D641G	missense	gain of function	FGFR3 D641G lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). D641G results in increased Fgfr3 autophosphorylation and substrate phosphorylation in cell culture (PMID: 26992226).
E686K	missense	unknown	FGFR3 E686K lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). E686K has been identified in the scientific literature (PMID: 19327639), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).
N540T	missense	unknown	FGFR3 N540T lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). N540T has been identified in the scientific literature (PMID: 9452043), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jan 2018).
N540K	missense	gain of function	FGFR3 N540K lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). N540K results in increased Fgfr3 autophosphorylation and substrate phosphorylation, and is transforming in cell culture (PMID: 26992226).
A257V	missense	unknown	FGFR3 A257V lies within the Ig-like C2 type domain 3 of the Fgfr3 protein (UniProt.org). A257V has been identified in sequencing studies (PMID: 27502722), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jun 2018).

Molecular Profile	Protein Effect	Treatment Approaches
EGFR L747_A750delinsP FGFR3-TACC3
FGFR3-TACC3	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor U0126
EGFR L858R FGFR3-TACC3
EGFR E746_A750del FGFR3-TACC3
FGFR2 fusion FGFR3 - TACC3
FGFR3 R248C	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 D786N	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 A391E	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 E360Q	loss of function - predicted
FGFR3 K413N	unknown
FGFR3 K650N	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 L794R	unknown
FGFR3 K650T	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 V677I	no effect
FGFR3 amp	no effect	FGFR Inhibitor (Pan) FGFR3 Antibody FGFR3 Inhibitor
ROS1 fusion ERBB2 amp FGFR3 amp RET amp
FGFR3 mut FGFR3 over exp
FGFR3 mutant	unknown
FGFR3 S371C	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 P283S	unknown
FGFR3 V306I	unknown
FGFR3 D764H	unknown
FGFR3 F384L	no effect
FGFR3 K319del	no effect - predicted
FGFR3 V172I	loss of function - predicted
FGFR3 T79S	unknown
FGFR3 R805Q	no effect - predicted
FGFR3 D646Y	no effect
FGFR3 L794fs	unknown
FGFR3 N653H	no effect
FGFR3 E456K	unknown
FGFR3 Y375C	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 inact mut	loss of function
FGFR3 G235D	unknown
FGFR3 D788N	unknown
FGFR3 E322K	unknown
FGFR3 V700A	unknown
FGFR3 S351C	loss of function - predicted
FGFR3 R669Q	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 Y647C	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 V50I	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 R640W	unknown
FGFR3 C582F	no effect
FGFR3 G197S	unknown
FGFR3 Y373C	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 Y373C FGFR3 over exp
AKT1 E17K FGFR3 Y373C
FGFR3 K508M	loss of function
FGFR3 G697C	no effect
FGFR3 I376C	unknown
FGFR3 dec exp KRAS mut
FGFR3 wild-type FGFR3 dec exp HRAS G12V
FGFR3 dec exp	no effect
FGFR3 R421Q	unknown
FGFR3 D617G	loss of function - predicted
FGFR3 S249C FGFR3 over exp
FGFR3 S249C	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 F386L	unknown
FGFR3 K652E	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 P795A	unknown
FGFR3 V329A	unknown
FGFR3 L645V	unknown
FGFR3 P253_I254insHIA	unknown
FGFR3 D762H	no effect - predicted
FGFR3 H643D	no effect
FGFR3 G382R	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 L608V FGFR3 V555M
FGFR3 V555M	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 N540S	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 V390M	no effect - predicted
FGFR3 S187Y	no effect - predicted
FGFR3 I538F	no effect
FGFR3 R603Q	unknown
FGFR3 S400fs	loss of function - predicted
FGFR3 D222N	unknown
FGFR3 fusion	unknown
FGFR3 S679F	unknown
FGFR3 R124W	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 G637W	loss of function - predicted
FGFR3 T394M	no effect - predicted
FGFR3 G65R	unknown
FGFR3 V630M	no effect
FGFR3 Q209H	unknown
FGFR3 P572A	no effect
FGFR3 V555L	unknown
FGFR3 G372C	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 G380R	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 K650E FGFR3 over exp HRAS K117E
FGFR3 K650E	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
HRAS K117E FGFR3 K650E
FGFR3 L608V	unknown
FGFR3 Y241C	unknown
FGFR3 R248H	unknown
FGFR3 K650Q	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 P91L	unknown
FGFR3 act mut	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 E216K	unknown
FGFR3 K715M	unknown
FGFR3 Q256R	unknown
FGFR3 A452S	no effect - predicted
FGFR3-BAIAP2L1	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 A634T	unknown
FGFR3 R112Q	unknown
FGFR3 K650M	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 wild-type	no effect
FGFR3 A391V	no effect - predicted
FGFR3 rearrange	unknown
FGFR3 G370C	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 C228R	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 R669G	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 V788M	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 G382D FGFR3 over exp
FGFR3 G382D	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 N540V	unknown
FGFR3 H274Y	no effect - predicted
FGFR3 I538V	gain of function - predicted	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3-ELAVL3	unknown
FGFR3 D785N	no effect - predicted
FGFR3 Y379C	unknown
FGFR3 E627D	no effect
FGFR3 R399C	no effect - predicted
FGFR3 G384D FGFR3 over exp
FGFR3 over exp	no effect	FGFR Inhibitor (Pan) FGFR3 Antibody FGFR3 Inhibitor
FGFR3 S433C	unknown
FGFR3 G384D	unknown
FGFR3 L385M	unknown
FGFR3 positive	unknown
FGFR2 pos FGFR3 pos
FGFR3 H349Y	unknown
FGFR3 R200C	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 S131L	unknown
FGFR3 V642M	no effect - predicted
FGFR3 S780C	no effect - predicted
FGFR3 E466K	no effect
FGFR3 A500T	no effect
FGFR3 G710D	unknown
FGFR3 D641N	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 P402S	no effect - predicted
FGFR3 A341T	unknown
FGFR3 D641G	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 E686K	unknown
FGFR3 N540T	unknown
FGFR3 N540K	gain of function	FGFR Inhibitor (Pan) FGFR3 Inhibitor
FGFR3 A257V	unknown

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
EGFR L747_A750delinsP FGFR3-TACC3	non-small cell lung carcinoma	predicted - resistant	Erlotinib	Clinical Study	Actionable	In a clinical study, a patient with non-small cell lung cancer initially responded to Tarceva (erlotinib), EGFR L747_A750delinsP and FGFR3-TACC3 were identified in post-progression tumor samples (PMID: 29883838).	29883838
FGFR3-TACC3	urinary bladder cancer	sensitive	FIIN-01	Preclinical	Actionable	In a preclinical study, FIIN-1 inhibited growth of the RT4 bladder cancer cell line, which has been demonstrated to harbor an FGFR3-TACC3 fusion, in culture (PMID: 20338520, PMID: 23175443).	23175443 20338520
FGFR3-TACC3	malignant glioma	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387).	22837387
FGFR3-TACC3	urinary bladder cancer	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ12908010 (AZ8010) induced cell cycle arrest and inhibited proliferation of urothelial cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 22869148, PMID: 23175443).	22869148 23175443
FGFR3-TACC3	non-small cell lung carcinoma	sensitive	Erdafitinib	Preclinical - Pdx	Actionable	In a preclinical study, Erdafitinib (JNJ-42756493) inhibited pERK signaling and tumor growth in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring FGFR3-TACC3 (PMID: 28341788).	28341788
FGFR3-TACC3	urinary bladder cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of bladder cancer cell lines harboring FGFR3-TACC3 fusion in culture (PMID: 27627808).	27627808
FGFR3-TACC3	urinary bladder cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited growth of bladder cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 24325461, PMID: 23175443).	23175443 24325461
FGFR3-TACC3	oligodendroglioma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of anaplastic oligodendroglioma harboring FGFR3-TACC3 fusion (PMID: 28978721).	28978721
FGFR3-TACC3	lung adenocarcinoma	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, BGJ398 inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908).	25294908
FGFR3-TACC3	transitional cell carcinoma	predicted - sensitive	Alpelisib + BGJ398	Phase I	Actionable	In a Phase Ib trial, BGJ398 and Alpelisib (BYL719) combination treatment resulted in partial response and a complete shrinkage of target lesions lasting 4 months in one urothelial carcinoma patient harboring a FGFR3-TACC3 fusion (J Clin Oncol 34, 2016 (suppl; abstr 2500)).	detail...
FGFR3-TACC3	urinary bladder cancer	sensitive	SU5402	Preclinical	Actionable	In a preclinical study, SU5402 induced cell-cycle arrest and inhibited proliferation of bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 21119661, PMID: 23175443).	21119661 23175443
FGFR3-TACC3	malignant glioma	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BJG398 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387).	22837387
FGFR3-TACC3	urinary system cancer	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I clinical trial, Erdafitinib (JNJ-42756493) treatment resulted in partial response in 2 urothelial cancer patients harboring FGFR3-TACC3 (PMID: 26324363).	26324363
FGFR3-TACC3	urinary bladder cancer	sensitive	LY2874455	Preclinical	Actionable	In a preclinical study, LY2874455 induced tumor regression in bladder cancer xenograft models that have been demonstrated to harbor an FGFR3-TACC3 fusion (PMID: 21900693, PMID: 23175443).	21900693 23175443
FGFR3-TACC3	urinary bladder cancer	sensitive	R3Mab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R3Mab inhibited FGFR3 signaling and tumor growth in bladder cancer cell line xenograft models harboring FGFR3-TACC3 (PMID: 25326231).	25326231
FGFR3-TACC3	bladder transitional cell papilloma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR3-TACC3	malignant glioma	sensitive	Erdafitinib	Preclinical	Actionable	In a preclinical study, Erdafitinib (JNJ-42756493) inhibited proliferation of glioma cells harboring FGFR3 - TACC3 fusion in culture and xenograft tumor growth in animal models (PMID: 25609060).	25609060
FGFR3-TACC3	bladder urothelial carcinoma	sensitive	PRN1371	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1371 inhibited proliferation of bladder transitional cell carcinoma cell lines harboring FGFR3-TACC3 fusion in culture and tumor growth in cell line xenograft models (PMID: 28978721).	28978721
FGFR3-TACC3	urinary bladder cancer	sensitive	E7090	Preclinical - Cell line xenograft	Actionable	In a preclinical study, urinary bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability, and antitumor activity in xenograft models (PMID: 27535969).	23175443 27535969
FGFR3-TACC3	glioblastoma multiforme	sensitive	U0126	Preclinical	Actionable	In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells expressing the FGFR3-TACC3 fusion in culture (PMID: 23298836).	23298836
FGFR3-TACC3	transitional cell carcinoma	sensitive	AZD4547 + BKM120	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line harboring FGFR3-TACC3 in culture, and inhibited tumor growth in xenograft models, with increased efficacy over either agent alone (PMID: 28108151).	28108151
FGFR3-TACC3	urinary bladder cancer	sensitive	ASP5878	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ASP5878 treatment inhibited proliferation of bladder cancer cell lines harboring a FGFR3-TACC3 fusion in culture, and resulted in tumor regression in a FGFR3-TACC3 positive bladder cancer cell line xenograft model (Mol Cancer Ther December 2015 14; A170).	detail...
FGFR3-TACC3	urinary bladder cancer	sensitive	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cell lines harboring an FGFR3-TACC3 fusion in culture and inhibited tumor growth in FGFR3-TACC3-positive bladder cancer cell line xenograft models (PMID: 25169980).	25169980
FGFR3-TACC3	urinary bladder cancer	sensitive	Pazopanib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to Votrient (pazopanib) in culture (PMID: 23558953).	23558953
FGFR3-TACC3	bladder transitional cell papilloma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR3-TACC3	urinary bladder cancer	no benefit	Selumetinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3-TACC were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR3-TACC3	malignant glioma	sensitive	PD173074	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 kinase activity and growth in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture and in cell line xenograft models (PMID: 22837387).	22837387
FGFR3-TACC3	transitional cell carcinoma	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in a patient with urothelial transitional cell carcinoma harboring FGFR3-TACC3 (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR3-TACC3	cervical squamous cell carcinoma	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in a patient with squamous cell carcinoma of the cervix harboring FGFR3-TACC3 (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR3-TACC3	glioblastoma multiforme	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in tumor reduction and stable disease in 2 glioblastoma multiforme patients harboring FGFR3 - TACC3 fusion (PMID: 25609060).	25609060
FGFR3-TACC3	glioblastoma multiforme	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in partial response in a glioblastoma patient harboring FGFR3 - TACC3 fusion (PMID: 26324363).	26324363
FGFR3-TACC3	lung adenocarcinoma	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatanib) inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908).	25294908
FGFR3-TACC3	Advanced Solid Tumor	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinicl study, AZD4547 inhibited proliferation of transformed cells over expressing FGFR3-TACC3 in culture (PMID: 26992226).	26992226
FGFR3-TACC3	urinary bladder cancer	sensitive	PRN1109	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PRN1109 treatment resulted in tumor regression in bladder cancer cell line xenograft models harboring FGFR3-TACC3 fusion (Eu J Cancer 2014 Vol 50, Suppl 6:157).	detail...
FGFR3-TACC3	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinicl study, Erdafitinib (JNJ-42756493) inhibited proliferation of transformed cells over expressing FGFR3-TACC3 in culture (PMID: 26992226).	26992226
FGFR3-TACC3	urinary bladder cancer	predicted - sensitive	S-49076	Preclinical	Actionable	In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 23804704, PMID: 23175443).	23175443 23804704
EGFR L858R FGFR3-TACC3	non-small cell lung carcinoma	resistant	Afatinib + Cetuximab	Clinical Study	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR L858R, whose disease progressed after initial response to Gilotrif (afatinib) and Erbitux (cetuximab) combination therapy (PMID: 29883838).	29883838
EGFR E746_A750del FGFR3-TACC3	non-small cell lung carcinoma	resistant	Naquotinib	Clinical Study	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Tarceva (erlotinib) followed by Naquotinib (ASP8273) (PMID: 29883838).	29883838
EGFR E746_A750del FGFR3-TACC3	non-small cell lung carcinoma	resistant	Osimertinib	Clinical Study	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Tarceva (erlotinib), followed by Tagrisso (osimertinib) (PMID: 29883838).	29883838
EGFR E746_A750del FGFR3-TACC3	non-small cell lung carcinoma	resistant	Afatinib	Clinical Study	Actionable	In a clinical study, FGFR3-TACC3 was identified as an acquired resistance mutation in a patient with non-small cell lung cancer harboring EGFR E746_A750del, whose disease progressed after initial response to Gilotrif (afatinib) (PMID: 29883838).	29883838
FGFR2 fusion FGFR3 - TACC3	adrenal carcinoma	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3 - TACC3 and FGFR2 - CCDC6 fusions (PMID: 26324363).	26324363
FGFR3 R248C	Advanced Solid Tumor	sensitive	Pazopanib	Preclinical - Cell culture	Actionable	In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).	23786770
FGFR3 R248C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-independent proliferation induced by FGFR3 R248C in cultured cells (PMID: 19381019).	19381019
FGFR3 R248C	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).	23786770
FGFR3 R248C	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).	23786770
FGFR3 amp	urinary system cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).	27401245
FGFR3 amp	Advanced Solid Tumor	predicted - sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, BGJ398 demonstrated safety and preliminary efficacy in patients with select solid tumors harboring FGFR alterations (Cancer Res October 1, 2014 74:CT326).	detail...
FGFR3 amp	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 59% (10/17) of patients with advanced solid tumors harboring FGFR amplification, with a 6-month progression-free survival rate of 15% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR3 amp	Advanced Solid Tumor	predicted - sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of several tumor cell lines with FGFR alterations in culture (Cancer Res April 15, 2011 71:3560).	detail...
FGFR3 amp	non-small cell lung carcinoma	sensitive	PRN1371	Preclinical - Pdx	Actionable	In a preclinical study, PRN1371 treatment resulted in 28.2% tumor growth inhibition in patient-derived xenograft models of FGFR3-amplified non-small cell lung cancer (PMID: 28978721).	28978721
FGFR3 amp	urinary system cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).	27401245
ROS1 fusion ERBB2 amp FGFR3 amp RET amp	non-small cell lung carcinoma	predicted - resistant	Crizotinib	Clinical Study	Actionable	In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).	29636358
FGFR3 mut FGFR3 over exp	urinary bladder cancer	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 33% (1/3) of non-muscle invasive bladder cancer patients harboring both FGFR3 mutations and FGFR3 over expression (J Clin Oncol 34, 2016 (suppl; abstr 4526)).	detail...
FGFR3 mutant	bladder urothelial carcinoma	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response in 33% (1/3) of patients with BCG-unresponsive, non-muscle-invasive, urothelial carcinoma of the bladder harboring FGFR3 mutations (PMID: 27932416).	27932416
FGFR3 mutant	urinary bladder cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 mutation in culture (PMID: 27550940).	27550940
FGFR3 mutant	Advanced Solid Tumor	sensitive	BGJ398	Preclinical	Actionable	In a preclinical study, tumor cell lines with FGFR3 mutations demonstrated sensitivity to BGJ398 in culture (PMID: 23002168).	23002168
FGFR3 mutant	transitional cell carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)).	detail...
FGFR3 mutant	transitional cell carcinoma	sensitive	BGJ398	Clinical Study	Actionable	In a clinical study, BGJ398 treatment led to 25.4% (17/67) confirmed responses and a disease control rate of 64% (43/67), which included complete responses, partial responses, and stable disease, and resulted in a median progression-free survival of 3.75 months and a median overall survival of 7.75 months (PMID: 29848605).	29848605
FGFR3 mutant	transitional cell carcinoma	predicted - sensitive	B-701 + Docetaxel	Phase Ib/II	Actionable	In a Phase I/II trial, B-701 in combination with Taxotere (docetaxel) demonstrated safety and preliminary efficacy, resulted in enhanced activity in patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 mutations or fusions comparing to wild-type patients (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534; NCT02401542).	detail...
FGFR3 mutant	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 40% (6/16) of patients with advanced solid tumors harboring FGFR single nucleotide variants, with a 6-month progression-free survival rate of 8% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR3 mutant	bladder urothelial carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, patients with bladder urothelial carcinoma harboring an FGFR3 mutation demonstrated a disease control rate of 75% (6/8) when treated with BGJ398, including 3 patients with a partial response and 3 with stable disease (PMID: 27870574; NCT01004224).	27870574
FGFR3 mutant	urinary system cancer	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in 25% tumor shrinkage at week 8 in an urothelial cancer patient harboring FGFR3 mutations (PMID: 26324363).	26324363
FGFR3 mutant	Advanced Solid Tumor	sensitive	Pemigatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).	detail...
FGFR3 mutant	transitional cell carcinoma	predicted - sensitive	Erdafitinib	Phase II	Actionable	In a Phase II trial, Erdafitinib (JNJ-42756493) treatment resulted in an objective response rate of 42% (40/96, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (J Clin Oncol 36, 2018 (suppl; abstr 4503); NCT02365597).	detail...
FGFR3 D764H	head and neck squamous cell carcinoma	no benefit	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D764H in culture, however, cells expressing FGFR3 D764H did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).	27053219
FGFR3 Y375C	urinary bladder cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).	22238366
FGFR3 Y375C	urinary bladder cancer	resistant	Nintedanib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3 Y375C were resistant to growth inhibition by Ofev (Nintedanib) in culture (PMID: 22238366).	22238366
FGFR3 Y375C	urinary bladder cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).	22238366
FGFR3 Y375C	urinary bladder cancer	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).	22238366
FGFR3 Y375C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-dependent proliferation of cells expressing FGFR3 Y375C in culture (PMID: 19381019).	19381019
FGFR3 Y375C	urinary bladder cancer	resistant	Cediranib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring an FGFR3 Y375C mutation were resistant to growth inhibition by Cediranib (AZD-2171) in culture (PMID: 22238366).	22238366
FGFR3 D788N	head and neck squamous cell carcinoma	no benefit	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D788N in culture, however, cells expressing FGFR3 D788N did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).	27053219
FGFR3 Y373C	myeloid neoplasm	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR3 Y373C	myeloid neoplasm	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 Y373C in culture (PMID: 25169980).	25169980
FGFR3 Y373C	multiple myeloma	sensitive	E7090	Preclinical - Cell culture	Actionable	In a preclinical study, a multiple myeloma cell line harboring FGFR3 Y373C (PMID: 19901323) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969).	19901323 27535969
FGFR3 Y373C	myeloid neoplasm	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR3 Y373C	myeloid neoplasm	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR3 Y373C FGFR3 over exp	multiple myeloma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 signaling and decreased proliferation and survival of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).	22869148
FGFR3 Y373C FGFR3 over exp	multiple myeloma	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).	22869148
AKT1 E17K FGFR3 Y373C	urinary bladder cancer	sensitive	AZD5363 + AZD4547	Preclinical	Actionable	In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323).	26351323
FGFR3 dec exp KRAS mut	lung cancer	no benefit	Trametinib	Preclinical	Actionable	In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).	27338794
FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	decreased response	AZ8010	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148).	22869148
FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	resistant	AZD4547	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148).	22869148
FGFR3 wild-type FGFR3 dec exp HRAS G12V	transitional cell carcinoma	resistant	PD173074	Preclinical	Actionable	In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148).	22869148
FGFR3 S249C FGFR3 over exp	transitional cell carcinoma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited growth of urothelial carcinoma (UC) cells expressing high levels of FGFR3 S249C, but had reduced efficacy against UC cells with low levels of FGFR3 S249C expression (PMID: 22869148).	22869148
FGFR3 S249C	urinary bladder cancer	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).	22238366
FGFR3 S249C	urinary bladder cancer	sensitive	Ponatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of bladder cancer cells harboring FGFR3 S249C in culture and in cell line xenograft models (PMID: 22238366).	22238366
FGFR3 S249C	renal pelvis transitional cell carcinoma	no benefit	RO4987655	Preclinical - Cell culture	Actionable	In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO4987655 in culture (PMID: 26438159).	26438159
FGFR3 S249C	renal pelvis transitional cell carcinoma	no benefit	Selumetinib	Preclinical - Cell culture	Actionable	In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).	26438159
FGFR3 S249C	renal pelvis transitional cell carcinoma	predicted - sensitive	Pazopanib	Clinical Study	Actionable	In a case study, a patient with urothelial carcinoma of the renal pelvis harboring FGFR3 S249C demonstrated a partial response lasting 9 months following treatment with Votrient (pazopanib) (PMID: 27271022).	27271022
FGFR3 S249C	urinary bladder cancer	sensitive	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cells harboring FGFR3 S249C in culture and inhibited tumor growth in FGFR3 S249C-positive bladder cancer cell line xenograft models (PMID: 25169980).	25169980
FGFR3 S249C	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited growth of transformed cells expressing FGFR3 S249C in culture (PMID: 23786770).	23786770
FGFR3 S249C	urinary system cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture (PMID: 27401245).	27401245
FGFR3 S249C	urinary bladder cancer	sensitive	ASP5878	Preclinical - Cell line xenograft	Actionable	In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring FGFR3 S249C in culture, and resulted in tumor regression in xenograft models (Mol Cancer Ther December 2015 14; A170).	detail...
FGFR3 S249C	urinary bladder cancer	resistant	Nintedanib	Preclinical	Actionable	In a preclinical study, bladder cancer cells harboring FGFR3 S249C were resistant to Ofev (Nintedanib) induced inhibition of cell proliferation in culture (PMID: 22238366).	22238366
FGFR3 S249C	Advanced Solid Tumor	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR3 S249C in culture (PMID: 23786770).	23786770
FGFR3 S249C	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing FGFR3 S249C in culture (PMID: 23786770).	23786770
FGFR3 S249C	renal pelvis transitional cell carcinoma	no benefit	RO5126766	Preclinical - Cell culture	Actionable	In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO5126766 in culture (PMID: 26438159).	26438159
FGFR3 S249C	urinary bladder cancer	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 S249C in culture (PMID: 22238366).	22238366
FGFR3 S249C	bladder carcinoma	sensitive	R3Mab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R3Mab decreased dimer formation and constitutive activation of FGFR3 S249C, and inhibited growth of bladder cancer cell lines harboring FGFR3 S249C in culture and in xenograft models (PMID: 19381019).	19381019
FGFR3 S249C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited proliferation of transformed cells expressing FGFR3 S249C in culture (PMID: 19381019).	19381019
FGFR3 S249C	urinary system cancer	sensitive	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 decreased Myc expression and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture and in xenograft models (PMID: 27401245).	27401245
FGFR3 S249C	urinary bladder cancer	sensitive	Cediranib	Preclinical	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited growth of bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).	22238366
FGFR3 S249C	bladder urothelial carcinoma	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response in a patient with BCG-unresponsive, non-muscle-invasive, urothelial carcinoma of the bladder harboring FGFR3 S249C (PMID: 27932416).	27932416
FGFR3 F386L	myeloid neoplasm	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 F386L in culture (PMID: 25169980).	25169980
FGFR3 K652E	urinary bladder cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of bladder cancer cells harboring FGFR3 K652E in culture (PMID: 27627808).	27627808
FGFR3 K652E	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-dependent cell proliferation in cells expressing FGFR3 K652E in culture (PMID: 19381019).	19381019
FGFR3 L608V FGFR3 V555M	transitional cell carcinoma	resistant	BGJ398	Clinical Study	Actionable	In a clinical study, a patient with metastatic urothelial carcinoma progressed while being treated with BGJ398 and subsequent cell-free DNA testing revealed FGFR3 V555M (also corresponds to V443M) and FGFR3 L608V (also corresponds to L496V) (PMID: 29848605).	29848605
FGFR3 V555M	Advanced Solid Tumor	decreased response	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880).	28034880
FGFR3 V555M	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).	28034880
FGFR3 V555M	Advanced Solid Tumor	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to BGJ398 in culture (PMID: 28034880).	28034880
FGFR3 V555M	Advanced Solid Tumor	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to AZD4547 in culture (PMID: 28034880).	28034880
FGFR3 V555M	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).	28034880
FGFR3 V555M	Advanced Solid Tumor	sensitive	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).	28034880
FGFR3 V555M	transitional cell carcinoma	resistant	BGJ398	Clinical Study	Actionable	In a clinical study, a patient with metastatic urothelial carcinoma progressed while being treated with BGJ398 and subsequent cell-free DNA testing revealed FGFR3 V555M (also corresponds to V443M) (PMID: 29848605).	29848605
FGFR3 V555M	Advanced Solid Tumor	decreased response	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).	28034880
FGFR3 fusion	transitional cell carcinoma	sensitive	BGJ398	Phase I	Actionable	In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)).	detail...
FGFR3 fusion	urinary bladder cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 fusion in culture (PMID: 27550940).	27550940
FGFR3 fusion	Advanced Solid Tumor	predicted - sensitive	AZD4547	Phase II	Actionable	In a Phase II (MATCH) trial, AZD4547 treatment resulted in partial response in 22% (2/9) and stable disease in 55% (5/9) of patients with advanced solid tumors harboring FGFR fusions, with a 6-month progression-free survival rate of 42% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).	detail...
FGFR3 fusion	transitional cell carcinoma	predicted - sensitive	B-701 + Docetaxel	Phase Ib/II	Actionable	In a Phase I/II trial, B-701 in combination with Taxotere (docetaxel) demonstrated safety and preliminary efficacy, resulted in enhanced activity in patients with locally advanced or metastatic urothelial carcinoma harboring FGFR3 mutations or fusions comparing to wild-type patients (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534; NCT02401542).	detail...
FGFR3 fusion	Advanced Solid Tumor	predicted - sensitive	TAS-120	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TAS-120 demonstrated growth inhibition and reduced FGFR phosphorylation in human cancer cell lines and xenograft models harboring FGFR mutations (Mol Cancer Ther 2013;12(11 Suppl):A270).	detail...
FGFR3 V555L	Advanced Solid Tumor	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 V555L demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).	28034880
FGFR3 V555L	transitional cell carcinoma	resistant	BGJ398	Clinical Study	Actionable	In a clinical study, two patients with metastatic urothelial carcinoma progressed while being treated with BGJ398 and subsequent cell-free DNA testing revealed FGFR3 V555L (also corresponds to V443M) (PMID: 29848605).	29848605
FGFR3 G372C	Advanced Solid Tumor	sensitive	R3Mab	Preclinical - Cell culture	Actionable	In a preclinical study, R3Mab inhibited ligand-dependent proliferation in cells expressing FGFR3 G372C (PMID: 19381019).	19381019
FGFR3 K650E FGFR3 over exp HRAS K117E	myeloid neoplasm	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148).	22869148
FGFR3 K650E FGFR3 over exp HRAS K117E	multiple myeloma	sensitive	PD173074	Preclinical	Actionable	In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148).	22869148
FGFR3 K650E	Advanced Solid Tumor	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to growth inhibition by AZD4547 in culture (PMID: 26992226).	26992226
FGFR3 K650E	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinicl study, Erdafitinib (JNJ-42756493) inhibited proliferation of transformed cells over expressing FGFR3 K560E in culture (PMID: 26992226).	26992226
FGFR3 K650E	Advanced Solid Tumor	sensitive	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).	28034880
FGFR3 K650E	Advanced Solid Tumor	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).	28034880
FGFR3 K650E	myeloid neoplasm	no benefit	SSR128129E	Preclinical	Actionable	In a preclinical study, SSR128129E did not inhibit proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562).	23597562
FGFR3 K650E	Advanced Solid Tumor	sensitive	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).	28034880
FGFR3 K650E	myeloid neoplasm	sensitive	SU5402	Preclinical - Cell culture	Actionable	In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562).	23597562
FGFR3 K650E	Advanced Solid Tumor	sensitive	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).	28034880
FGFR3 K650E	Advanced Solid Tumor	sensitive	PD98059	Preclinical	Actionable	In a preclinical study, PD98059 inhibited FGFR3 K650E-induced transformation of cells in culture (PMID: 14534538).	14534538
FGFR3 K650E	myeloid neoplasm	sensitive	FF-284	Preclinical	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 K650E in culture (PMID: 25169980).	25169980
FGFR3 K650E	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).	28034880
FGFR3 K650E	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).	28034880
FGFR3 L608V	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).	28034880
FGFR3 L608V	Advanced Solid Tumor	decreased response	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).	28034880
FGFR3 L608V	Advanced Solid Tumor	sensitive	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).	28034880
FGFR3 L608V	Advanced Solid Tumor	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).	28034880
FGFR3 L608V	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).	28034880
FGFR3 L608V	Advanced Solid Tumor	decreased response	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to AZD4547 in culture (PMID: 28034880).	28034880
FGFR3 L608V	Advanced Solid Tumor	sensitive	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).	28034880
FGFR3 act mut	urinary bladder cancer	predicted - sensitive	S-49076	Preclinical	Actionable	In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells over expressing constitutively active FGFR3 in culture (PMID: 23804704).	23804704
FGFR3 act mut	Advanced Solid Tumor	decreased response	Cediranib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR3 act mut	Advanced Solid Tumor	sensitive	FF-284	Phase I	Actionable	In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR3 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).	detail...
FGFR3 act mut	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).	22238366
FGFR3 act mut	Advanced Solid Tumor	sensitive	Erdafitinib	Phase I	Actionable	In a Phase I trial, Erdafitinib (JNJ-42756493) treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).	26324363
FGFR3 act mut	Advanced Solid Tumor	no benefit	Brivanib	Preclinical	Actionable	In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).	22238366
FGFR3 act mut	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).	22238366
FGFR3 act mut	Advanced Solid Tumor	decreased response	Nintedanib	Preclinical	Actionable	In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).	22238366
FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Cediranib	Preclinical - Cell culture	Actionable	In a preclinical study, Cediranib (AZD-2171) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).	25589496
FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	ASP5878	Preclinical - Cell culture	Actionable	In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (Mol Cancer Ther December 2015 14; A170).	detail...
FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).	25589496
FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	FF-284	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Debio 1347 decreased phosphorylation of ERK and FRS and inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture, and inhibited tumor growth in bladder cancer cell line xenograft models with FGFR3-BAIAP2L1 (PMID: 25589496)	25589496
FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, Debio 1347 inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (PMID: 25169980).	25169980
FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).	25589496
FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).	25589496
FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of bladder cancer cells harboring FGFR3-BAIAP2L1 fusion in culture (PMID: 27627808).	27627808
FGFR3-BAIAP2L1	Advanced Solid Tumor	sensitive	Derazantinib	Preclinical - Cell culture	Actionable	In a preclinical study, Derazantinib (ARQ 087) inhibited growth of transformed cells expressing FGFR3-BAIAP2L1 in culture (PMID: 27627808).	27627808
FGFR3-BAIAP2L1	urinary bladder cancer	sensitive	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, BGJ398 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).	25589496
FGFR3 K650M	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR3 K650M in culture (PMID: 28978721).	28978721
FGFR3 wild-type	urinary bladder cancer	resistant	Ponatinib	Preclinical	Actionable	In a preclinical study, bladder cancer cells with wild-type FGFR3 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).	22238366
FGFR3 wild-type	bladder carcinoma	sensitive	R3Mab	Preclinical - Cell line xenograft	Actionable	In a preclinical study, R3Mab decreased wild-type FGFR3 activation, thereby inhibited cell proliferation of FGFR3 wild-type human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019).	19381019
FGFR3 wild-type	myeloid neoplasm	sensitive	SU5402	Preclinical - Cell culture	Actionable	In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562).	23597562
FGFR3 wild-type	myeloid neoplasm	sensitive	SSR128129E	Preclinical	Actionable	In a preclinical study, SSR128129E inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562).	23597562
FGFR3 rearrange	myeloid neoplasm	sensitive	AZD4547	Preclinical - Cell line xenograft	Actionable	In a preclinical study, AZD4547 inhibited survival of myeloma cells harboring FGFR3 translocation in culture and in cell line xenograft models (PMID: 27550940).	27550940
FGFR3 rearrange	myeloid neoplasm	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of myeloma cells harboring FGFR3 rearrangements in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).	detail...
FGFR3 G384D FGFR3 over exp	multiple myeloma	decreased response	AZ8010	Preclinical	Actionable	In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZ8010 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).	22869148
FGFR3 G384D FGFR3 over exp	multiple myeloma	decreased response	AZD4547	Preclinical	Actionable	In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZD4547 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).	22869148
FGFR3 G384D FGFR3 over exp	multiple myeloma	decreased response	PD173074	Preclinical	Actionable	In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to PD173074 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).	22869148
FGFR3 over exp	glioblastoma multiforme	sensitive	U0126	Preclinical	Actionable	In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells over-expressing Fgfr3 in culture (PMID: 23298836).	23298836
FGFR3 over exp	urinary bladder cancer	sensitive	Sorafenib + BEZ235	Preclinical - Pdx	Actionable	In a preclinical study, the combination of BEZ235 and Nexavar (sorafenib) resulted in improved progression-free survival in an FGFR3-over expressing patient-derived xenograft (PDX) model of bladder cancer with secondary resistance to BGJ398 due to reactivation of downstream signaling, as evidenced by increased activation of Akt and Erk (PMID: 26270481).	26270481
FGFR3 over exp	Advanced Solid Tumor	sensitive	LY2874455	Preclinical	Actionable	In a preclinical study, LY2874455 induced tumor regression in FGFR3-over expressing bladder and multiple myeloma xenograft models (PMID: 21900693).	21900693
FGFR3 over exp	urinary bladder cancer	sensitive	SU5402	Preclinical	Actionable	In a preclinical study, SU5402 inhibited growth of bladder cancer cells over expressing wild-type FGFR3 in culture (PMID: 21119661).	21119661
FGFR3 over exp	transitional cell carcinoma	sensitive	AZ8010	Preclinical	Actionable	In a preclinical study, AZ8010 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148).	22869148
FGFR3 over exp	transitional cell carcinoma	sensitive	AZD4547	Preclinical	Actionable	In a preclinical study, AZD4547 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148).	22869148
FGFR3 over exp	urinary bladder cancer	sensitive	Dovitinib	Phase II	Actionable	In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 8% (1/13) of non-muscle invasive bladder cancer patients over expressing FGFR3 (J Clin Oncol 34, 2016 (suppl; abstr 4526)).	detail...
FGFR3 over exp	urinary bladder cancer	sensitive	BGJ398	Preclinical - Pdx	Actionable	In a preclinical study, treatment with BGJ398 led to improved progression-free survival in a patient-derived xenograft (PDX) model of bladder cancer with FGFR3 over expression (PMID: 26270481).	26270481
FGFR3 over exp	Advanced Solid Tumor	sensitive	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation in transformed cells overexpressing wild-type FGFR3 in culture (PMID: 28978721).	28978721
FGFR3 over exp	head and neck squamous cell carcinoma	sensitive	Rogaratinib	Preclinical	Actionable	In a preclinical study, Rogaratinib (BAY 1163877) inhibited tumor growth in a head and neck squamous cell carcinoma xenograft model with FGFR3 overexpression (Cancer Res August 1, 2015 75:772).	detail...
FGFR3 over exp	multiple myeloma	sensitive	MFGR1877S	Phase I	Actionable	In a Phase I trial, MFGR1877S demonstrated safety and resulted in stable disease in 42% (6/14) of multiple myeloma patients overexpressing FGFR3 (Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4029).	detail...
FGFR3 positive	lung squamous cell carcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR3 positive	stomach cancer	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive gastric cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR3 positive	lung adenocarcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung adenocarcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR3 positive	head and neck squamous cell carcinoma	predicted - sensitive	Rogaratinib	Phase I	Actionable	In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR3-positive head and neck squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).	detail...
FGFR2 pos FGFR3 pos	breast carcinoma	sensitive	E7090	Preclinical	Actionable	In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969).	27535969
FGFR3 S131L	head and neck squamous cell carcinoma	decreased response	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, a head and neck squamous cell carcinoma cell line expressing FGFR3 S131L demonstrated decreased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 in culture (PMID: 27053219).	27053219
FGFR3 N540K	Advanced Solid Tumor	decreased response	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880).	28034880
FGFR3 N540K	Advanced Solid Tumor	decreased response	FF-284	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).	28034880
FGFR3 N540K	Advanced Solid Tumor	sensitive	Erdafitinib	Preclinical - Cell culture	Actionable	In a preclinicl study, Erdafitinib (JNJ-42756493) inhibited proliferation of transformed cells over expressing FGFR3 K560E in culture (PMID: 26992226).	26992226
FGFR3 N540K	Advanced Solid Tumor	resistant	BGJ398	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K were resistant to BGJ398 in culture (PMID: 28034880).	28034880
FGFR3 N540K	Advanced Solid Tumor	sensitive	Ponatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880).	28034880
FGFR3 N540K	Advanced Solid Tumor	sensitive	Dovitinib	Preclinical - Cell culture	Actionable	In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880).	28034880
FGFR3 N540K	Advanced Solid Tumor	resistant	AZD4547	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K were reistant to growth inhibition by AZD4547 in culture (PMID: 26992226).	26992226
FGFR3 N540K	Advanced Solid Tumor	decreased response	LY2874455	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to LY2874455 in culture (PMID: 28034880).	28034880

Gene Symbol	FGFR3
Synonyms	ACH \| CD333 \| CEK2 \| HSFGFR3EX \| JTK4
Gene Description	FGFR3 is a receptor tyrosine kinase activated upon binding of the FGF ligand, which activates RAS-MAPK and PI3K-AKT pathways. Altered function of FGFR3 in cancer may lead to increased cell proliferation and decreased apoptosis (PMID: 22508544).
Entrez Id	2261
Chromosome	4
Map Location	4p16.3
Canonical Transcript	NM_000142